Tag:
Threshold Pharmaceuticals
Latest Headlines
Latest Headlines
Threshold Pharma lands $20M milestone from Merck KGaA
Threshold Pharmaceuticals reported this morning that Merck KGaA is handing over a $20 million milestone for a successful mid-stage study of their pancreatic cancer drug.
Threshold shares spike on positive IIb data for pancreatic cancer drug
Threshold Pharmaceuticals ( $THLD ) put out the word this morning that its experimental therapy TH-302 delayed the progression of advanced, aggressive pancreatic cancer by two months in a Phase IIb...
Threshold, Merck KGaA strike $525M licensing deal for promising cancer drug
The dealmakers at South San Francisco-based Threshold Pharmaceuticals ($THLD) have crafted a $525 million licensing pact with Merck KGaA covering its late-stage cancer drug TH-302. Threshold snagged
Threshold raises $35M
Threshold Pharmaceuticals has raised $35 million from the sale of shares to institutional investors. "Response assessments in over 90 solid tumor patients suggest that TH-302 is active in monotherapy
Mixed data from two Threshold cancer trials
California-based Threshold Pharmaceuticals has released an update on its glufosfamide program. According to the company's release, a Phase II trial of the drug for soft tissue sarcoma "provided
Threshold slashes staff in effort to cut burn rate
Refocusing its R&D efforts, Threshold Pharmaceuticals is cutting its 44-person workforce down to 32--including two senior executives. Threshold plans to concentrate on its hypoxia-activated
